Retinal vascular events after intravitreal bevacizumab
December 22nd, 2009 Posted by: admin
Purpose: To record retinal vascular events following intravitreal bevacizumab injection.Methods: Collaborative multi-centre retrospective case series.Results: Eight patients were documented to have central retinal artery occlusion (four patients), branch retinal artery occlusion, capillary occlusion, central retinal vein occlusion and branch retinal vein occlusion (one patient each) within 0[ndash]55 days (median 2 weeks) of intravitreal bevacizumab. All patients had several ocular and systemic risk factors for retinal vascular events: elevated intraocular pressure on discharge (four patients), pre-existent glaucoma (one patient), pre-existent ischaemic retinal vascular disorder (four patients), systemic hypertension (five patients), diabetes mellitus (three patients), coronary artery disease (four patients), carotid disease (three patients), smoking (two patients) and migraine (one patient).Conclusion: The retinal vascular events may be associated with the underlying ocular disease under treatment or with the underlying systemic disease, may be related to an increased intraocular pressure post-injection constraining further an already poor retinal perfusion, the vasoconstrictor effect of bevacizumab, or a combination of all three.
Similar Posts:
- Visual improvement in central retinal vein occlusion (CRVO) following intravitreal injections of bevacizumab (Avastin®)
- Intravitreal anti-vascular endothelial growth factor therapy with bevacizumab for tuberous sclerosis with macular oedema
- Intravitreal ranibizumab for macular oedema secondary to retinal vein occlusion: a retrospective study of 34 eyes
- Effect of acute postural variation on diabetic macular oedema
- Ultrasound assessment of short-term ocular vascular effects of intravitreal injection of bevacizumab (Avastin®) in neovascular age-related macular degeneration
- Combined intravitreal bevacizumab and triamcinolone in exudative age-related macular degeneration
- Profound retinal ischaemia after ranibizumab administration in an eye with ocular ischaemic syndrome
- Increase of vascular endothelial growth factor and interleukin-6 in the aqueous humour of patients with macular oedema and central retinal vein occlusion
- Efficacy of intravitreal bevacizumab (Avastin®) therapy for early and advanced neovascular age-related macular degeneration
- Long-term study of vascular perfusion effects following arteriovenous sheathotomy for branch retinal vein occlusion